Results 51 to 60 of about 1,077,721 (136)

Psilocybin, From Ancestral Use to Therapeutic Potential: A Multidimensional Review of Its Pharmacological Basis and Current Perspectives

open access: yesHuman Psychopharmacology: Clinical and Experimental, Volume 41, Issue 5, September 2026.
ABSTRACT Objective This review critically examines psilocybin, with particular emphasis on its pharmacokinetics and pharmacodynamics, including its serotonergic, neuroplastic, and anti‐inflammatory mechanisms. It integrates historical context, preclinical and clinical evidence, and evaluates emerging therapeutic potential, safety, microdosing practices,
José Norberto Vásquez‐Bonilla
wiley   +1 more source

Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy

open access: yesSubstance Abuse Treatment, Prevention, and Policy, 2022
International drug policy is rapidly evolving in tandem with promising evidence for psychedelic-assisted psychotherapy (PAP) in treating a range of mental health conditions.
Victor Mocanu   +3 more
doaj   +1 more source

Music Playlist Use in Clinical Trials of Psychedelic Assisted Psychotherapy: A Systematic Review

open access: yesJournal of Clinical Psychology, Volume 82, Issue 9, Page 1263-1270, September 2026.
ABSTRACT Recent studies have shown promising results for psychedelics in the treatment of psychiatric disorders. Both in clinical and recreational settings, contextual elements, such as music, can influence the experience of users and may be linked to positive outcomes.
Lucas Cruz   +4 more
wiley   +1 more source

Long‐Term Therapy Experiences in Post‐suicidal Men: Safety, Gender and Iatrogenic Harm

open access: yesMultiPsych, Volume 1, Issue 3, September 2026.
Men who have survived a suicide attempt and engaged in long‐term psychotherapy describe the therapeutic relationship as the primary agent of recovery—not technique, but sustained relational presence. Gender dynamics, developmental history and institutional failure all shape engagement. These findings challenge short‐term service models and carry direct
Alastair Coomes, Joel Vos, Ron Roberts
wiley   +1 more source

THE RE-EMERGENCE OF A PSYCHIATRIC PARADIGM : A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY OF MDMA-ASSISTED AND PSILOCYBIN-ASSISTED PSYCHOTHERAPY FOR PTSD AND MDD

open access: yes, 2023
Psychedelic research became throttled in the 1970s, though the clinical interest for psychedelics has seen a resurgence in the last couple of decades for their application as psychotherapy-adjunct substances used to treat various psychological disorders.
Johansson, Andreas
core   +3 more sources

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 345-356, August 2026.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le   +8 more
wiley   +1 more source

The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression? [PDF]

open access: yesExploration of Neuroscience
Treatment resistant depression (TRD) is frequently encountered in clinical practice. The lack of response of the condition to conventional medications and augmentation strategies has spawned the search for novel treatment approaches.
Trevor R. Norman
doaj   +1 more source

Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 94-108, July 2026.
Interest in ayahuasca and its main component, N,N‐Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited.
Tijana Stojanović   +4 more
wiley   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 14, Page 4048-4057, July 2026.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt   +3 more
wiley   +1 more source

Psilocybin as a novel treatment for chronic pain

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 14, Page 3992-4005, July 2026.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy